Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | PKM | P14618 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4248562 | 0.85 | GAA (0.44) | GAASMN1; SMN2ALDH1A1KMT2APDE4B | |
| SCHEMBL4245845 | 0.84 | GYS1 (0.34) | GAASMN1; SMN2MEN1KMT2A | |
| SCHEMBL12379064 | 0.84 | ALDH1A1 (0.31) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL13293484 | 0.79 | ALDH1A1 (0.45) | GAASMN1; SMN2ALDH1A1PKMMEN1 | |
| SCHEMBL12377613 | 0.75 | POLB (0.41) | GAASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL4240861 | 0.75 | HPGD (0.50) | SMN1; SMN2ALDH1A1PDE4BLMNA | |
| SCHEMBL12377614 | 0.74 | HTT (0.36) | GAASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL4245711 | 0.73 | GYS1 (0.40) | ALDH1A1PDE4BHSD11B1 | |
| SCHEMBL12377618 | 0.73 | NPC1 (0.45) | LMNA | |
| SCHEMBL12377617 | 0.72 | LMNA (0.40) | SMN1; SMN2ALDH1A1LMNACHRNB2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003699-B2 | Amide compound and use thereof for controlling plant diseases | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-23 | — | — | US | disclosed |
| US-7902400-B2 | N-(1,1-diemthylpropyl)-4-(2-propynyloxy)-3-methoxybenzamide; N-(2,2-diemthylpropyl)-4-(2-propynyloxy)-3-methoxybenzamide; controlling plant diseases | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20100105647-A1 | AMIDE COMPOUND AND USE THEREOF FOR CONTROLLING PLANT DISEASES | SUMITOMO CHEMICAL COMPANY, LIMITED | 2010-04-29 | — | — | US | disclosed |
| US-20100069499-A1 | AMIDE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20090131531-A1 | Amide Compounds and their Use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131531-A1 | Amide Compounds and their Use | NAT1, ACAT2, NAAA | GAA 251/4885SMN1; SMN2 1812/4885ALDH1A1 1905/4885 |
| US-20100069499-A1 | AMIDE COMPOUND AND USE THEREOF | CBR1, CBR3, GBA1 | GAA 1309/4885SMN1; SMN2 3032/4885ALDH1A1 2111/4885 |
| US-20100105647-A1 | AMIDE COMPOUND AND USE THEREOF FOR CONTROLLING PLANT DISEASES | CYC1, CBR3, CBR1 | GAA 1837/4885SMN1; SMN2 3629/4885ALDH1A1 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.